FindTrial
Sign In

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00040625
Enrollment
Unknown
Registered
2002-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2007-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesothelioma

Brief summary

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Interventions

DRUGPemetrexed
DRUGCisplatin

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery * Prior chemotherapy for your disease is allowed * Measurable lesion is not required * Have a adequate performance status * Sign an informed consent form

Exclusion criteria

* You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study * You are excluded from this trial if you have received radiation within the previous 2 weeks * You are excluded from this trial if you are a candidates for curative surgery

Countries

Brazil, Egypt, Saudi Arabia, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026